8-K: Applied Therapeutics Announces Positive Clinical Trial Results and Secures $100 Million in Private Placement

Applied Therapeutics reports positive clinical trial results for govorestat in SORD Deficiency and Galactosemia, secures $100 million in private placement, and anticipates extended cash runway into 2026.

Summary

• Applied Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company's New Drug Application (NDA) for govorestat to treat Classic Galactosemia was accepted by the FDA and granted Priority Review, with a PDUFA target action date of August 28, 2024.
• A Marketing Authorization Application (MAA) for govorestat is also under review by the European Medicines Agency (EMA), with a decision expected in the fourth quarter of 2024.
• The company announced positive results from a 12-month interim analysis of the INSPIRE Phase 3 trial of govorestat in SORD Deficiency, showing a statistically significant correlation between sorbitol levels and clinical outcomes.
• Applied Therapeutics completed a $100 million private placement, which is expected to extend the company's cash runway into 2026.
• The company's cash and cash equivalents totaled $49.9 million as of December 31, 2023, and increased to approximately $153.5 million as of March 1, 2024, after the private placement.
• Research and development expenses for 2023 were $53.9 million, compared to $55.6 million in 2022.
• General and administrative expenses decreased to $20.6 million in 2023 from $27.3 million in 2022.
• The net loss for 2023 was $119.8 million, or $1.42 per share, compared to a net loss of $82.5 million, or $2.18 per share, in 2022.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant regulatory and clinical milestones achieved, as well as the successful private placement. The company's financial position has been strengthened, and the outlook is optimistic. However, the net loss and the change in fair value of warrant liabilities temper the overall sentiment slightly.

Positives

• The acceptance of the NDA for govorestat and the granting of Priority Review by the FDA are significant regulatory milestones.
• Positive interim results from the INSPIRE Phase 3 trial for SORD Deficiency indicate the potential efficacy of govorestat.
• The $100 million private placement significantly strengthens the company's financial position.
• The company's cash runway is expected to extend into 2026, providing financial stability for ongoing operations and development.
• The company has made progress in reducing operating expenses, particularly in general and administrative costs.

Negatives

• The company reported a net loss of $119.8 million for the year ended December 31, 2023.
• The change in fair value of warrant liabilities resulted in a significant expense of $56.573 million.

Risks

• The company's future success depends on the regulatory approval of its drug candidates.
• Clinical trials may not always yield positive results, and there is a risk that the company's drug candidates may not be effective or safe.
• The company may need to raise additional capital in the future, which could dilute existing shareholders.
• The company faces competition from other pharmaceutical companies developing treatments for similar diseases.
• There are risks associated with the commercialization of new drugs, including market acceptance and pricing.

Future Outlook

The company expects its cash and cash equivalents, combined with the proceeds from the private placement and potential milestones, will fund the business into 2026. They also plan to request a pre-NDA meeting with the FDA for govorestat in SORD Deficiency and are awaiting regulatory decisions on govorestat for Galactosemia.

Management Comments

• Shoshana Shendelman, PhD, Founder, Chief Executive Officer, and Chair of the Board, stated that the company has made significant clinical and regulatory progress, particularly with the NDA acceptance and MAA validation for govorestat.
• She also noted that the recent positive data from the interim analysis of the INSPIRE study in SORD Deficiency confirms the role of sorbitol as a key driver of disease progression.

Industry Context

This announcement is significant for the rare disease biopharmaceutical sector, as it highlights the progress of Applied Therapeutics in developing treatments for unmet medical needs. The positive clinical trial results and regulatory advancements could position the company as a leader in the treatment of Galactosemia and SORD Deficiency. The successful private placement also demonstrates investor confidence in the company's pipeline and strategy.

Comparison to Industry Standards

• The FDA's acceptance of the NDA and granting of Priority Review for govorestat is a positive sign, as it indicates the agency's recognition of the potential of the drug to address an unmet medical need. This is comparable to other companies that have received priority review for rare disease treatments, such as BioMarin Pharmaceutical's Vimizim for Morquio A Syndrome.
• The positive results from the INSPIRE Phase 3 trial are also encouraging, as they demonstrate a statistically significant correlation between sorbitol levels and clinical outcomes. This is similar to other successful clinical trials in the rare disease space, such as Sarepta Therapeutics' eteplirsen for Duchenne muscular dystrophy.
• The $100 million private placement is a significant amount of funding for a clinical-stage biopharmaceutical company, and it is comparable to other successful private placements in the sector. For example, companies like Ultragenyx Pharmaceutical have raised similar amounts of capital to fund their drug development programs.
• The company's cash runway into 2026 is also a positive sign, as it provides financial stability for ongoing operations and development. This is comparable to other well-funded biopharmaceutical companies, such as Vertex Pharmaceuticals, which have a strong cash position to support their research and development efforts.

Stakeholder Impact

• Shareholders will benefit from the increased cash runway and potential for future revenue from approved drugs.
• Employees will have job security due to the company's improved financial position.
• Patients with Galactosemia and SORD Deficiency may have access to new treatment options.
• The company's suppliers and partners will benefit from the company's continued operations and growth.
• Creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company plans to request a pre-NDA meeting with the FDA for govorestat in SORD Deficiency.
• The company will continue to develop its pipeline candidates.
• The company will present full results from the ARISE-HF Phase 3 study at an upcoming medical conference.
• The company will continue to assess clinical outcomes of the ongoing INSPIRE trial at 24 months.
• The company will await the FDA's decision on the govorestat NDA by August 28, 2024.
• The company will await the EMA's decision on the govorestat MAA in the fourth quarter of 2024.

Key Dates

Keywords

govorestat, Galactosemia, SORD Deficiency, NDA, MAA, FDA, EMA, clinical trial, private placement, biopharmaceutical, rare disease, AT-007, AT-001, Diabetic Cardiomyopathy, INSPIRE Phase 3, cash runway